JP2012021028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012021028A5 JP2012021028A5 JP2011223318A JP2011223318A JP2012021028A5 JP 2012021028 A5 JP2012021028 A5 JP 2012021028A5 JP 2011223318 A JP2011223318 A JP 2011223318A JP 2011223318 A JP2011223318 A JP 2011223318A JP 2012021028 A5 JP2012021028 A5 JP 2012021028A5
- Authority
- JP
- Japan
- Prior art keywords
- immunotherapeutic agent
- composition according
- adjuvant
- allogeneic
- atcc crl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002955 immunomodulating agent Substances 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 8
- 230000000735 allogeneic effect Effects 0.000 claims 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 210000002307 prostate Anatomy 0.000 claims 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- 239000008150 cryoprotective solution Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 208000023958 prostate neoplasm Diseases 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 241001446247 uncultured actinomycete Species 0.000 claims 2
- 239000012646 vaccine adjuvant Substances 0.000 claims 2
- 229940124931 vaccine adjuvant Drugs 0.000 claims 2
- 241000186361 Actinobacteria <class> Species 0.000 claims 1
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 1
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000004388 Interleukin-4 Human genes 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 102000000704 Interleukin-7 Human genes 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 201000005702 Pertussis Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 108010055044 Tetanus Toxin Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000002577 cryoprotective agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000016784 immunoglobulin production Effects 0.000 claims 1
- 229940032219 immunotherapy vaccine Drugs 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 229940117681 interleukin-12 Drugs 0.000 claims 1
- 229940028885 interleukin-4 Drugs 0.000 claims 1
- 229940100994 interleukin-7 Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 229940118376 tetanus toxin Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9827104.2A GB9827104D0 (en) | 1998-12-10 | 1998-12-10 | New cancer treatments |
| GB9827104.2 | 1998-12-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000586359A Division JP4949554B2 (ja) | 1998-12-10 | 1999-12-09 | ガンの新規処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012021028A JP2012021028A (ja) | 2012-02-02 |
| JP2012021028A5 true JP2012021028A5 (OSRAM) | 2012-05-17 |
Family
ID=10843926
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000586359A Expired - Fee Related JP4949554B2 (ja) | 1998-12-10 | 1999-12-09 | ガンの新規処置 |
| JP2011223318A Pending JP2012021028A (ja) | 1998-12-10 | 2011-10-07 | ガンの新規処置 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000586359A Expired - Fee Related JP4949554B2 (ja) | 1998-12-10 | 1999-12-09 | ガンの新規処置 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US6972128B1 (OSRAM) |
| EP (1) | EP1137422B1 (OSRAM) |
| JP (2) | JP4949554B2 (OSRAM) |
| KR (1) | KR20010090874A (OSRAM) |
| AT (1) | ATE304365T1 (OSRAM) |
| AU (1) | AU763485B2 (OSRAM) |
| CA (1) | CA2354045C (OSRAM) |
| CZ (1) | CZ300499B6 (OSRAM) |
| DE (1) | DE69927286T2 (OSRAM) |
| ES (1) | ES2249046T3 (OSRAM) |
| GB (1) | GB9827104D0 (OSRAM) |
| HU (1) | HUP0104568A3 (OSRAM) |
| IL (2) | IL143296A0 (OSRAM) |
| MX (1) | MXPA01005816A (OSRAM) |
| NO (1) | NO327044B1 (OSRAM) |
| NZ (1) | NZ512004A (OSRAM) |
| PL (1) | PL201016B1 (OSRAM) |
| WO (1) | WO2000033869A2 (OSRAM) |
| ZA (1) | ZA200104164B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9827104D0 (en) * | 1998-12-10 | 1999-02-03 | Onyvax Ltd | New cancer treatments |
| GB9827103D0 (en) * | 1998-12-10 | 1999-02-03 | Onyvax Ltd | New cancer treatments |
| WO2000071156A2 (en) * | 1999-05-21 | 2000-11-30 | Onyvax Limited | New vaccine formulations-3 |
| CA2404388C (en) * | 2000-04-01 | 2010-06-15 | Onyvax Limited | New prostate cell lines |
| US6667479B2 (en) * | 2001-06-01 | 2003-12-23 | Raytheon Company | Advanced high speed, multi-level uncooled bolometer and method for fabricating same |
| US20050019336A1 (en) | 2003-07-23 | 2005-01-27 | Dalgleish Angus George | Human prostate cell lines in cancer treatment |
| JP2007503435A (ja) * | 2003-08-26 | 2007-02-22 | ベクトン・ディキンソン・アンド・カンパニー | 治療薬の皮内送達法 |
| KR101183705B1 (ko) * | 2007-02-07 | 2012-09-17 | 사이단호진한다이비세이부쯔뵤우겐큐우카이 | 암의 치료제 |
| JPWO2009066462A1 (ja) * | 2007-11-20 | 2011-04-07 | 日本電気株式会社 | 細胞傷害性ｔ細胞の誘導方法、細胞傷害性ｔ細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン |
| AU2009200767A1 (en) * | 2008-03-10 | 2009-09-24 | Aristocrat Technologies Australia Pty Limited | A gaming system and a method of gaming |
| WO2010057197A1 (en) | 2008-11-17 | 2010-05-20 | The Regents Of The University Of Michigan | Cancer vaccine compositions and methods of using the same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2120503C (en) * | 1991-10-04 | 2006-04-04 | Glenn Dranoff | The regulation of systemic immune responses utilizing cytokines and antigens |
| JPH05246889A (ja) * | 1992-03-05 | 1993-09-24 | Seitai Chiyousetsu Kenkyusho:Kk | 制癌方法および制癌剤 |
| WO1995029704A1 (en) * | 1994-04-28 | 1995-11-09 | Scott Freeman | Cell lines obtained by in vivo migration and by fusion with autoimmune cells |
| CA2214503C (en) * | 1995-03-17 | 2002-05-07 | The Regents Of The University Of California | Method for treating tumors |
| US5788963A (en) * | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
| ES2191784T3 (es) * | 1995-12-28 | 2003-09-16 | Univ Johns Hopkins Med | Vacunas de tumores de citocinas paracrinas alogenicas. |
| WO1997028255A1 (en) * | 1996-02-02 | 1997-08-07 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer |
| GB9620350D0 (en) * | 1996-09-30 | 1996-11-13 | Maudsley David J | Cancer vaccine |
| US6207805B1 (en) * | 1997-07-18 | 2001-03-27 | University Of Iowa Research Foundation | Prostate cell surface antigen-specific antibodies |
| GB9827104D0 (en) * | 1998-12-10 | 1999-02-03 | Onyvax Ltd | New cancer treatments |
-
1998
- 1998-12-10 GB GBGB9827104.2A patent/GB9827104D0/en not_active Ceased
-
1999
- 1999-12-09 DE DE69927286T patent/DE69927286T2/de not_active Expired - Lifetime
- 1999-12-09 AU AU16683/00A patent/AU763485B2/en not_active Ceased
- 1999-12-09 ES ES99959542T patent/ES2249046T3/es not_active Expired - Lifetime
- 1999-12-09 NZ NZ512004A patent/NZ512004A/en unknown
- 1999-12-09 EP EP99959542A patent/EP1137422B1/en not_active Expired - Lifetime
- 1999-12-09 CA CA2354045A patent/CA2354045C/en not_active Expired - Fee Related
- 1999-12-09 KR KR1020017007096A patent/KR20010090874A/ko not_active Ceased
- 1999-12-09 PL PL348828A patent/PL201016B1/pl not_active IP Right Cessation
- 1999-12-09 WO PCT/GB1999/004129 patent/WO2000033869A2/en not_active Ceased
- 1999-12-09 MX MXPA01005816A patent/MXPA01005816A/es active IP Right Grant
- 1999-12-09 CZ CZ20012032A patent/CZ300499B6/cs not_active IP Right Cessation
- 1999-12-09 US US09/857,691 patent/US6972128B1/en not_active Expired - Lifetime
- 1999-12-09 IL IL14329699A patent/IL143296A0/xx active IP Right Grant
- 1999-12-09 HU HU0104568A patent/HUP0104568A3/hu unknown
- 1999-12-09 AT AT99959542T patent/ATE304365T1/de not_active IP Right Cessation
- 1999-12-09 JP JP2000586359A patent/JP4949554B2/ja not_active Expired - Fee Related
-
2001
- 2001-05-22 IL IL143296A patent/IL143296A/en not_active IP Right Cessation
- 2001-05-22 ZA ZA200104164A patent/ZA200104164B/en unknown
- 2001-05-29 NO NO20012634A patent/NO327044B1/no not_active IP Right Cessation
-
2005
- 2005-07-12 US US11/178,415 patent/US8034360B2/en not_active Expired - Fee Related
-
2011
- 2011-10-07 JP JP2011223318A patent/JP2012021028A/ja active Pending
- 2011-10-11 US US13/270,820 patent/US20120164099A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012021028A5 (OSRAM) | ||
| CA2354046A1 (en) | New cancer treatments | |
| JP2002531521A5 (OSRAM) | ||
| ES2848064T3 (es) | Vacuna terapéutica potenciadora de inmunidad para VPH y enfermedades relacionadas | |
| Zheng et al. | Applications of bacillus Calmette–Guerin and recombinant bacillus Calmette–Guerin in vaccine development and tumor immunotherapy | |
| WO2007022151A3 (en) | Immunization of avians by administration of non-replicating vectored vaccines | |
| JP2013536240A5 (OSRAM) | ||
| Johansen et al. | New routes for allergen immunotherapy | |
| JP2015533376A5 (OSRAM) | ||
| JP2020528911A5 (OSRAM) | ||
| Xiang et al. | Promising particle-based vaccines in cancer therapy | |
| WO2009114085A3 (en) | Allogeneic cancer cell-based immunotherapy | |
| EP2385059A3 (en) | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma | |
| JP2014139185A5 (OSRAM) | ||
| Rong et al. | Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine | |
| JP2015526469A5 (OSRAM) | ||
| JP2002531520A5 (OSRAM) | ||
| Domingos-Pereira et al. | Intravaginal and subcutaneous immunization induced vaccine specific CD8 T cells and tumor regression in the bladder | |
| CA2354045A1 (en) | New cancer treatments | |
| RU2013143741A (ru) | Терапевтическая вакцина против рака | |
| AR097881A1 (es) | FORMULACIÓN INMUNOGÉNICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTÍGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSIÓN QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADYUVANTE, APTA PARA SU USO FARMACÉUTICO | |
| CN115443333A (zh) | 一种基因编辑的造血干细胞及其与car-t细胞的联合应用 | |
| CN102219835B (zh) | 基于hca587抗原的长肽及其在制备抗肿瘤药物方面的应用 | |
| Johansen et al. | Parenteral vaccine administration: tried and true | |
| BRPI0606165A2 (pt) | método de indução de uma resposta imunológica de célula t de memória contra pelo menos um antìgeno em um paciente humano, uso de uma composição imunogênica que compreende um vetor de vìrus de infecção virulenta não-replicante ou emparelhado de replicação que expressa o produto de tradução de um gene de ag85a micobacterial, uso de um antìgeno na manufatura de um medicamento para o tratamento de uma doença em um paciente mediante a indução de uma resposta imunológica de célula t de memória central e vacina vetorada |